Novo Nordisk’s High Risk/Reward Proposition: 129% Rally Or 65% Drop?

Novo Nordisk A/S (NOVO-B) has entered the 18th and final phase of its long-term Weekly Adhishthana Cycle, marking a potentially transformative period. While the weekly charts point to a possible Nirvana, which represents the highest price of the stock throughout its 18 phases, there are conflicting signals coming from the monthly charts as well as the company’s NYSE ADR (NYSE:NVO).

Read the full article on Benzinga for deeper insights into the Adhishthana Cycle, the stock’s recent trajectory, and expert commentary.